Ozcan Met

Kongens Lyngby, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 89 publications

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-free adoptive TIL therapy.

Journal: Journal for immunotherapy of cancer

Published: July 27, 2026

Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen.

Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen.

Journal: Signal transduction and targeted therapy

Published: February 20, 2026

Driving CAR therapies beyond T cells.

Driving CAR therapies beyond T cells.

Journal: Trends in cancer

Published: December 02, 2025

Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells.

Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells.

Journal: Signal transduction and targeted therapy

Published: November 28, 2025

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 27, 2025

Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Phenotypic and Functional Characteristics of CD8+ T cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 27, 2025

Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.

Tumor Infiltrating Lymphocyte Therapy Combined With PD-1/LAG-3 Inhibition in Patients With Recurrent Platinum-Resistant Ovarian Cancer.

Journal: International journal of cancer

Published: September 16, 2025

Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates.

Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates.

Journal: Signal transduction and targeted therapy

Published: September 09, 2025

ProS1-MerTK signaling in CD4 T cells: implications for TIL expansion and functionality.

ProS1-MerTK signaling in CD4 T cells: implications for TIL expansion and functionality.

Journal: Oncoimmunology

Published: July 14, 2025

Harnessing Arginase-2-specific CD8+ T cells to target immunosuppressive Cutaneous T cell Lymphoma.

Harnessing Arginase-2-specific CD8+ T cells to target immunosuppressive Cutaneous T cell Lymphoma.

Journal: The British journal of dermatology

Published: July 01, 2025

Harnessing arginase 2-specific CD8+ T cells to target immunosuppressive cutaneous T-cell lymphoma.

Harnessing arginase 2-specific CD8+ T cells to target immunosuppressive cutaneous T-cell lymphoma.

Journal: The British journal of dermatology

Published: July 01, 2025

Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering.

Tumour-infiltrating lymphocyte therapy comes of age in the era of genetic engineering.

Journal: The Lancet. Oncology

Published: May 03, 2025

Showing 1-12 of 89

Last Updated: 09/26/2026